1st RNA Editing Summit 2019

Date: 19-Nov-19 to 20-Nov-19
Location: Revere Hotel Boston Common / Boston / United States
Category: Healthcare & Pharmaceuticals Conferences & Trade Fairs

As CRISPR genome editing struggles to overcome key specificity and delivery challenges in its pursuit to realize therapeutic applications, the 1st RNA Editing Summit 2019 accelerates the translation and commercialization of RNA editing for an array of research and therapeutic applications.
As the therapeutic potential of RNA editing explodes, discover the fundamental mechanisms of RNA editing, such as recruiting endogenous ADARs with encodable guideRNAs, and learn about the novel approaches being developed to precisely and efficiently deliver intended RNA edits.
Join RNA, functional genomic, cell biology and immuno-oncology experts from large pharma, biotech and academia at the 1st RNA Editing Summit 2019 in the pursuit of translating emerging RNA editing mechanisms into therapeutic reality.


Eli Eisenberg,Professor Tel, Aviv University, Maria Montiel Gonzalez Scientist, RNA editing platform, Beam Therapeutics, Erez Levanon, Professor, Bar-Ilan University, Gene Yeo, Professor, University of California, San Diego, Nina Papavasiliou, University Professor and Division Head German Cancer Research Center, Heidelberg, Germany Visiting Professor, Rockefeller University, New York, Jonathan Gootenberg, McGovern Fellow, McGovern Institute for Brain Research, MIT, Dr. Joshua Rosenthal, Senior Scientist, Marine Biological Laboratory, Omar Abudayyeh, McGovern Fellow, the McGovern Institute for Brain Research MIT, Thorsten Stafforst, Professor, University of Tuebingen, Yi-Tao Yu, Principal Investigator and Professor, University of Rochester Medical Centre, Hyo Min Park, CTO & co-founder, GenEdit, Scott Ribich, Vice President, Biology, Accent Therapeutics, U. Thomas Meier, Professor, Albert Einstein College of Medicine, Jeffrey Ostrove, CEO & Director, Locana, Alan Herbert, Founder & Head of Discovery, InsideOutBio, Francois Vigneault, Co-Founder, President & CEO, Shape Therapeutics, Jin Billy Li, Associate Professor, Stanford University, Michael Jantsch, Professor Medical, University of Vienna, Oliver Rausch, Chief Scientific Officer, STORM Therapeutics, David Rodman, Executive VP R&D, ProQR, Andrew Fraley, Founder & SVP Technology, Korro Bio, Prashant Mali, Assistant Professor, Bioengineering, University of San Diego

Go to event website